123Fozard JR (September 2000). "BP-294 Ste Civile Bioprojet". Current Opinion in Investigational Drugs. 1 (1): 86–89. PMID11249601.
1234Rouleau A, Garbarg M, Ligneau X, Mantion C, Lavie P, Advenier C, etal. (June 1997). "Bioavailability, antinociceptive and antiinflammatory properties of BP 2-94, a histamine H3 receptor agonist prodrug". The Journal of Pharmacology and Experimental Therapeutics. 281 (3): 1085–1094. doi:10.1016/S0022-3565(24)36743-6. PMID9190840.
1234Rouleau A, Stark H, Schunack W, Schwartz JC (October 2000). "Anti-inflammatory and antinociceptive properties of BP 2-94, a histamine H(3)-receptor agonist prodrug". The Journal of Pharmacology and Experimental Therapeutics. 295 (1): 219–225. doi:10.1016/S0022-3565(24)38890-1. PMID10991982.
↑Soldani G, Bertini S, Rouleau A, Schwartz JC, Coruzzi G (December 1999). "Gastric antisecretory effects of compound BP 2-94: a histamine H3-receptor agonist prodrug". Digestive Diseases and Sciences. 44 (12): 2380–2385. doi:10.1023/a:1026606231771. PMID10630485.
↑Monti JM, Jantos H, Ponzoni A, Monti D (July 1996). "Sleep and waking during acute histamine H3 agonist BP 2.94 or H3 antagonist carboperamide (MR 16155) administration in rats". Neuropsychopharmacology. 15 (1): 31–35. doi:10.1016/0893-133X(95)00151-3. PMID8797189.
↑Thakkar MM (February 2011). "Histamine in the regulation of wakefulness". Sleep Medicine Reviews. 15 (1): 65–74. doi:10.1016/j.smrv.2010.06.004. PMC3016451. PMID20851648. Oral administration of BP 2.94 (20e30 mg/kg) produces a dosedependent increase in NREM sleep without affecting wakefulness or REM sleep in rats. Pretreatment with H3 receptor antagonist carboperamide (30 mg/kg) blocks the sleep inducing effects of BP 2.94 in rats. Conversely, oral administration of carboperamide (20e30 mg/kg) produces a dose-dependent increase in wakefulness with a concomitant decrease in NREM and REM sleep.60 Similarly, oral administration of H3 receptor agonist BP 2.94 induces a dramatic increase in NREM sleep in cats.61
↑Lin JS (October 2000). "Brain structures and mechanisms involved in the control of cortical activation and wakefulness, with emphasis on the posterior hypothalamus and histaminergic neurons". Sleep Medicine Reviews. 4 (5): 471–503. doi:10.1053/smrv.2000.0116. PMID17210278. Indeed, as shown in Figure 6, oral application of BP2-94, a H3-receptor agonist (kindly provided by Bioprojet, Paris, France) induces a dramatic increase in the power spectral density of cortical slow activity in the cat, accompanied by a significant increase in SWS [23], whereas, in contrast, oral application of ciproxifan, a H3-receptor antagonist (also from Bioprojet, see Ref. 99), causes total suppression of cortical slow activity and spindles and marked enhancement of fast rhythms, and consequently induces waking (see details in Fig. 7).
